HEPATITIS-B VACCINE ADMINISTERED TO CHRONIC CARRIERS OF HEPATITIS-B SURFACE-ANTIGEN
HEPATITIS-B VACCINE ADMINISTERED TO CHRONIC CARRIERS OF HEPATITIS-B SURFACE-ANTIGEN
复制标题
DOI：
10.7326/0003-4819-96-5-575
复制
发表时间：
1982-01-01
影响因子：
39.2
通讯作者：
SZMUNESS, W
中科院分区：
文献类型：
--
作者：
DIENSTAG, JL;STEVENS, CE;SZMUNESS, W
对16名慢性B型肝炎表面抗原（HBsAg）携带者进行了长达6个月的B型肝炎疫苗接种，试图消除该抗原。该疫苗中的HBsAg不同于天然抗原。无一例HBsAg消除，但10例患者中有1例不再携带B e抗原（HBeAg）。在13例无HBsAg抗体（抗-HBs）的患者中，无一人获得抗体; 3例存在异型抗-HBs的患者中有2例抗-HBs滴度一过性低水平升高。8例患者血清丙氨酸氨基转移酶（ALT）水平下降，6例保持不变，2例一过性升高。ALT和HBeAg清除率降低似乎与疫苗接种无关，一过性ALT升高似乎代表散发性急性非甲非乙型肝炎。除手臂疼痛和关节疼痛外，未观察到其他不良反应。慢性乙型肝炎表面抗原携带者接种乙型肝炎疫苗虽然对消除乙型肝炎表面抗原无效，但似乎是安全的。B型肝炎疫苗。这种安全性如果得到证实，将简化B型肝炎疫苗接种计划的设计。
Up to 6 monthly doses of hepatitis B vaccine was administered to 16 chronic carriers of hepatitis B surface antigen (HBsAg) in an attempt to eliminate the antigen. The HBsAg in this vaccine differs from native antigen. No patient had elimination of HBsAg, but 1 of 10 no longer carried hepatitis B e antigen (HBeAg). Of 13 patients without preexisting antibody to HBsAg (anti-HBs), none acquired the antibody; 2 of 3 patients with preexisting heterotypic anti-HBs had transient, low-level increases in anti-HBs titers. Serum alanine aminotransaminase (ALT) levels fell in 8 patients, remained unchanged in 6, and increased transiently in 2. Decreased ALT and HBeAg clearance did not seem to be related to vaccination, and the transient ALT elevations appeared to represent sporadic, acute non-A, non-B hepatitis. No adverse effects other than sore arm and joint pain were seen. Immunization of chronic HBsAg carriers with hepatitis B vaccine, although ineffective in eliminating HBsAg, appeared to be safe. Such safety, if confirmed, would simplify the design of hepatitis B vaccination programs.